TAEUS® Platform Expansion
Tissue Temperature Monitoring (e.g., surgery)
Key Facts
About ENDRA Life Sciences
ENDRA Life Sciences is on a mission to revolutionize point-of-care diagnostics by enhancing the capabilities of conventional ultrasound. Its core achievement is the development of the TAEUS® platform, which is CE-marked for liver fat quantification in Europe, targeting the vast, underserved market for early detection of fatty liver disease. The company's strategy leverages a capital-efficient, accessory-based business model to integrate with existing ultrasound systems, aiming to establish TAEUS® as a new standard of care in hepatology and expand into other tissue characterization applications.
View full company profileAbout ENDRA Life Sciences
ENDRA Life Sciences is on a mission to revolutionize point-of-care diagnostics by enhancing the capabilities of conventional ultrasound. Its core achievement is the development of the TAEUS® platform, which is CE-marked for liver fat quantification in Europe, targeting the vast, underserved market for early detection of fatty liver disease. The company's strategy leverages a capital-efficient, accessory-based business model to integrate with existing ultrasound systems, aiming to establish TAEUS® as a new standard of care in hepatology and expand into other tissue characterization applications.
View full company profileAbout ENDRA Life Sciences
ENDRA Life Sciences is on a mission to revolutionize point-of-care diagnostics by enhancing the capabilities of conventional ultrasound. Its core achievement is the development of the TAEUS® platform, which is CE-marked for liver fat quantification in Europe, targeting the vast, underserved market for early detection of fatty liver disease. The company's strategy leverages a capital-efficient, accessory-based business model to integrate with existing ultrasound systems, aiming to establish TAEUS® as a new standard of care in hepatology and expand into other tissue characterization applications.
View full company profile